Dr. Hutson Gives an Analysis of the Phase III ATLAS Trial in RCC​

Introduction and Review of the COMPARZ Trial in Renal Cell CarcinomaПодробнее

Dr. Balar on Phase III ASSURE Trial Results for RCCПодробнее

Hutson: Emerging Targeted Therapies in RCCПодробнее

Dr. Thomas Hutson on Drug Sequencing in Renal Cell CarcinomaПодробнее

Robert J. Motzer, MD, elaborates on key findings from the Phase III CLEAR trialПодробнее

Dr. Larkin on Lenvatinib Plus Everolimus in Patients With RCCПодробнее

Subgroup analyses of METEOR; randomized phase III trial of cabozantinib vs everolimus for RCCПодробнее

Dr. Hutson Discusses the Phase III ATLAS Study in RCCПодробнее

Dr. Hutson on Tivozanib for Renal Cell CarcinomaПодробнее

Understanding and Working With New Immunotherapeutic and Targeted Management Models in Advanced RCCПодробнее

RCC First-Line Toxicity ConsiderationsПодробнее

Dr. Hutson on Lenvatinib/Everolimus Combo in RCCПодробнее

Clinical trials in adjuvant RCCПодробнее

A Phase III Trial of Pembrolizumab as Adjuvant Treatment for Renal Cell CarcinomaПодробнее

Dr. Rini Discusses the VEGF Targeted Agent AxitinibПодробнее

METEOR trial: cabozantinib vs everolimus in advanced renal cell carcinomaПодробнее

Advanced RCC Sequencing ChallengesПодробнее

PROSPER RCC study of perioperative nivolumab for renal cell carcinoma - future trialПодробнее

Dr. Choueiri on CABOSUN Trial Results in RCCПодробнее